Simmons Bank Has $3.04 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Simmons Bank grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 7.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,074 shares of the company’s stock after buying an additional 2,663 shares during the period. Simmons Bank’s holdings in AstraZeneca were worth $3,044,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its holdings in AstraZeneca by 17.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after acquiring an additional 9,002,450 shares in the last quarter. Capital World Investors raised its holdings in AstraZeneca by 0.3% in the 1st quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock valued at $634,525,000 after acquiring an additional 29,497 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in AstraZeneca by 16.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock valued at $266,565,000 after acquiring an additional 488,644 shares in the last quarter. Clearbridge Investments LLC raised its holdings in AstraZeneca by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after acquiring an additional 186,010 shares in the last quarter. Finally, Fayez Sarofim & Co raised its holdings in AstraZeneca by 4.7% in the 1st quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock valued at $202,588,000 after acquiring an additional 134,784 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AZN. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Trading Up 0.6 %

Shares of AZN stock opened at $65.19 on Wednesday. The firm has a market capitalization of $202.13 billion, a P/E ratio of 31.49, a P/E/G ratio of 1.20 and a beta of 0.47. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The stock’s fifty day simple moving average is $76.20 and its 200 day simple moving average is $78.47.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.